Vutrisiran
Studies of vutrisiran, an RNA interference therapy for transthyretin amyloidosis.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 0, 2, 1, 2, 2.
New guidelines and consensus this year
- Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical GuidanceJ Am Coll Cardiol2026 Feb 10
All papers from the last 12 months
81 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Disease-Modifying Therapy Uptake in Transthyretin Amyloid Cardiomyopathy: A 10-Year US Analysis of 77,000 Patients Across Three Approved AgentsJ Nucl Cardiol2026 Oct 14PMID 42874836
- Continuous Vutrisiran Reduces Cardiovascular Events and Hospitalizations in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B One-Year Open Label ExtensionJ Card Fail2026 Oct 11PMID 42860179
- Preliminary Real-World Evidence of Clinical and Echocardiographic Changes After Vutrisiran Initiation in Patients With Variant Transthyretin Amyloid Cardiomyopathy in Non-Endemic Regions: A Single-Center Observational StudyCirc Rep2026 Oct 9PMID 42856951
- Arrhythmias in patients with transthyretin cardiac amyloidosis and the impact of contemporary disease-modifying therapiesJ Cardiovasc Med (Hagerstown)2026 Oct 1PMID 42886847Review
- [Carpal Tunnel Syndrome and Lumbar Spinal Stenosis: When to Suspect Amyloidosis and How to Proceed with the Diagnostic Work-up]Brain Nerve2026 OctPMID 42864788Review
- Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical TrialJAMA Cardiol2026 Oct 1PMID 42646924RCT
- Efficacy of vutrisiran in a patient with hereditary transthyretin amyloidosis following heart and liver transplantationMed Clin (Barc)2026 OctPMID 42628290
- Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical TrialJAMA Cardiol2026 Oct 1PMID 42616515RCT
- Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRIJAMA Cardiol2026 Oct 1PMID 42584913RCT
- Disease-Modifying Therapies for Hereditary Transthyretin Amyloidosis with Polyneuropathy: Current Status and Future PerspectivesNeurol Ther2026 OctPMID 42458194Review
More cardiology trends
All specialties →Factor XI inhibitors
A newer class of anticoagulants that target factor XI or XIa.
Key point: Adding an FXIa inhibitor to standard antiplatelet therapy after acute noncardioembolic ischemic stroke or TIA reduces stroke recurrence without evidence of increased bleeding risk.
Colchicine in cardiovascular disease
Colchicine as an anti-inflammatory therapy in coronary and cardiovascular disease.
Key point: Low-dose colchicine has demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent.
Renal denervation
A catheter procedure targeting renal nerves to lower blood pressure.
Intravascular lithotripsy
Shockwaves delivered through a balloon catheter to crack calcium in arteries.
New antihypertensive drugs
New blood pressure drugs, including aldosterone synthase inhibitors and zilebesiran.
Key point: Aldosterone-targeted therapies, including aldosterone-synthase inhibitors and spironolactone, provide clinically meaningful systolic blood pressure reductions in resistant hypertension without increasing serious adverse events.
CETP inhibitors
Drugs that block cholesteryl ester transfer protein, studied for lowering LDL cholesterol.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
vutrisiran[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.